☆ 4.5 Editorial Material

A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

LUNG CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

Chao Lv et al.

Summary: This study evaluated the efficacy and safety of the third-generation EGFR tyrosine kinase inhibitor, osimertinib, as neoadjuvant therapy in patients with resectable EGFR-mutant non-small-cell lung cancer. The results showed that osimertinib treatment had satisfying efficacy and an acceptable safety profile, making it a promising neoadjuvant therapy for patients with resectable EGFR-mutant NSCLC.

LUNG CANCER (2023)

添加到收藏夹

Article Oncology

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Megan E. Daly et al.

Summary: This article provides evidence-based recommendations for the management of patients with stage III non-small-cell lung cancer (NSCLC). The recommendations were developed through a literature search and expert consensus, covering various aspects of evaluation, surgery, neoadjuvant and adjuvant approaches, and management of unresectable stage III NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

Mari Mino-Kenudson et al.

Summary: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has become the main treatment for advanced lung cancers. However, only a subset of patients respond to ICIs. The use of programmed death-ligand 1 (PD-L1) protein expression and tumor mutational burden (TMB) as predictive biomarkers has limitations. Ongoing research aims to find better immunotherapy biomarkers for treatment response and prognosis.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study

Yang Zhang et al.

Summary: The study aimed to investigate the efficacy and safety of neoadjuvant gefitinib in patients with stage II-IIIA NSCLC. The results showed that neoadjuvant therapy with gefitinib was safe and may be a viable treatment option for these patients, with potential for improved survival in those with major pathologic response.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)

添加到收藏夹

Article Oncology

P03.02 Osimertinib as Neoadjuvant Therapy for Resectable EGFR Mutant Non-small Cell Lung Cancer: A Real-World Multicenter Retrospective Study

X. Leng et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

C. Blakely et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

P47.10 Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study

W. Kian et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Lei Zhong et al.

Summary: Targeted therapeutic drugs have become mainstream cancer treatments due to their advantages in efficacy and safety, but still face challenges such as low response rate and drug resistance. A comprehensive review was conducted on small-molecule targeted anti-cancer drugs to promote their development, discussing current challenges and providing insights and perspectives for future research and development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Barzin Y. Nabet et al.

CELL (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Liwen Xiong et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. E. Postmus et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.